HRJR7T.jpg

Harnessing The Power of
NK Cells to Defeat Cancer

 
 
iPSCimage%20(2)_edited.jpg

"Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."

- Daniel Teper, Cytovia Therapeutics CEO

 

Cytovia In The News

 
Microphones_edited.jpg

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Antibodies

August 12th, 2020

Cytovia CEO Daniel Teper to present new EGFR Dual-Targeting CAR NK program at LifeSci Partners Summer Symposium (Wednesday, Aug 5th 9AM ET)

August 3rd, 2020

Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn